Semaglutide Plus Therapy Cuts Heavy Drinking by 41%, Landmark Lancet Study Finds

The first randomized controlled trial to test a GLP-1 receptor agonist for alcohol use disorder has yielded striking results. Patients receiving weekly semaglutide injections alongside cognitive behavioral therapy reduced their heavy drinking days by 41.1%—a 13.7% greater reduction than those receiving standard therapy alone.

Published in The Lancet and conducted by researchers at Copenhagen University Hospital with support from the National Institutes of Health, the study represents a significant advance in the search for new pharmacological treatments for alcohol use disorder. Current FDA-approved medications for the condition remain vastly underutilized, leaving a substantial treatment gap that researchers hope GLP-1 drugs might help address.

The Study Design

The research team specifically enrolled 108 treatment-seeking adults who met diagnostic criteria for both alcohol use disorder and obesity—a population that represents a significant portion of those struggling with problematic drinking. Participants were randomly assigned to receive either semaglutide or placebo injections once weekly for 26 weeks, with all participants simultaneously receiving standard cognitive behavioral therapy.

Throughout the trial, researchers collected both self-reported drinking data and objective biomarkers including blood-alcohol measurements. This dual approach strengthened the reliability of findings, particularly given that participants knew they were receiving an injection that could cause gastrointestinal side effects—a potential source of unblinding in pharmacological trials.

Measuring the Impact

The primary outcome told a clear story. Participants in the semaglutide group experienced an average reduction of roughly 12 heavy drinking days per month compared to baseline—a 50% higher reduction than the placebo group. Blood biomarker measurements corroborated these self-reports, showing consistent patterns of reduced alcohol consumption.

Beyond drinking outcomes, the study documented expected metabolic benefits. Participants receiving semaglutide showed more pronounced decreases in body weight and blood pressure compared to the placebo group. These ancillary benefits could prove clinically meaningful for a population with dual metabolic and substance use concerns.

Perhaps most intriguing from a treatment efficacy perspective was the calculated number needed to treat (NNT). At 4.3, semaglutide's NNT in this study compares favorably to existing medications for alcohol use disorder, which typically show NNT values of 7 or higher. This metric suggests that for every four to five patients treated with semaglutide plus therapy, one additional patient would achieve meaningful reduction in heavy drinking compared to therapy alone.

Understanding the Mechanism

Why would a drug developed for diabetes and obesity help reduce alcohol consumption? The answer lies in the brain's reward circuitry. GLP-1 receptors are expressed in brain regions associated with reward processing, impulse control, and addiction. By activating these receptors, semaglutide appears to modulate the dopaminergic response to alcohol, potentially reducing the reinforcing effects that drive continued use.

"We're beginning to see some of that potential for GLP-1s to treat drug addiction turn into reality," said Dr. Nora Volkow, director of NIH's National Institute on Drug Abuse and a study co-author. "Questions remain but this is nonetheless very encouraging."

The findings build upon earlier research that suggested GLP-1 drugs might benefit substance use disorders. A previous clinical trial found no effect on heavy drinking in the overall study population, but a subset of participants with obesity showed a strong response—prompting the current study's focused design.

Clinical Implications

For clinicians treating patients with co-occurring alcohol use disorder and obesity, the study offers a potentially valuable new tool. Semaglutide is already widely prescribed for weight management, meaning many patients who might benefit from its alcohol-related effects are already receiving it—though likely without the structured behavioral therapy component that appeared essential in this trial.

The study's focus on patients with both conditions raises important questions about generalizability. Would semaglutide show similar benefits for individuals with alcohol use disorder but normal body weight? The researchers explicitly designed this trial to test the hypothesis generated by subgroup analyses of earlier studies, but broader populations remain to be studied.

Adverse effects in the trial were consistent with semaglutide's known safety profile—primarily gastrointestinal symptoms that were transient and mild. This tolerability profile compares favorably to some existing medications for alcohol use disorder, which can cause significant side effects that limit adherence.

The Path Forward

Study authors acknowledge the need for longer-duration trials in larger populations to confirm these findings. The 26-week intervention period, while substantial, leaves questions about durability of effect unanswered. Additionally, the relatively small sample size, while adequate for detecting the observed effect, limits precision in estimating the true magnitude of benefit.

The research team, led by Dr. Mette Kruse Klausen and Dr. Anders Fink-Jensen at Copenhagen University Hospital, plans to pursue these questions in subsequent studies. If confirmed in larger trials, semaglutide could become the first new pharmacological option for alcohol use disorder in years—and the first that simultaneously addresses the metabolic complications that frequently accompany heavy drinking.

For a condition that affects millions of Americans and contributes to approximately 140,000 deaths annually, any advance in treatment options carries significant public health weight. The convergence of obesity and addiction epidemics in the United States means that a medication addressing both could find a substantial patient population.

What This Means for Treatment

The study's results suggest that medication-assisted treatment for alcohol use disorder may be entering a new phase. Rather than relying solely on medications developed specifically for addiction, clinicians may increasingly turn to drugs with broader metabolic effects that incidentally modulate reward pathways.

This approach aligns with growing recognition of addiction as a complex condition involving multiple physiological systems. The brain's reward circuitry does not operate in isolation—it is intimately connected with metabolic regulation, stress response, and immune function. Medications that address these interconnected systems may prove more effective than those targeting single neurotransmitter pathways.

For patients currently struggling with alcohol use disorder, particularly those with concurrent obesity, the findings offer hope for more effective treatment options. While semaglutide is not yet approved specifically for alcohol use disorder, the strength of these results suggests that such an indication may be pursued—potentially expanding the therapeutic arsenal against a persistent and deadly condition.